Tetramer Research & Development Contract (Influenza)

四聚体研究

• 批准号: 10678192
• 负责人: JOHN ALTMAN
• 金额: $ 20万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-21 至 2027-03-20
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10678192
• 关键词: Antigen Presentation Pathway; Area; Bar Codes; Binding Sites; Biotin; Communicable Diseases; Communities; Contracts; Core Facility; DNA; Disease; Immune; Immunology; Influenza; MHC Class II Genes; Mediating; Mesocricetus auratus; Oligonucleotides; Performance; Production; Reagent; Research; Resources; Stains; Streptavidin; T cell response; T-Cell Activation; T-Lymphocyte; Technology; Time; United States National Institutes of Health; Variant; cost; fluorophore; influenzavirus; neoplastic cell; novel; pathogenic microbe; research and development

The NIH Tetramer Core Facility provides valuable resources to the research community that enable cutting edge research in basic immunology and a wide variety of infectious disease areas (including the influenza virus) via production and distribution of class I, class II and CD1 reagents. The reagents are being applied to studies of antigen processing and presentation, T cell activation, T cell responses against microbial pathogens or tumors, and T cell-mediated exacerbation or amelioration of immune-mediated diseases. This contract conducts research and development that would enhance the quality, functionality (e.g., sensitivity), and breadth of available tetramer reagents and decrease production time.

美国国立卫生研究院四聚体核心设施通过生产和销售I类、II类和CD1类试剂，为研究界提供了宝贵的资源，使基础免疫学和各种传染病领域(包括流感病毒)的尖端研究成为可能。这些试剂正被应用于抗原处理和提呈、T细胞激活、T细胞对微生物病原体或肿瘤的反应以及T细胞介导的免疫介导性疾病的恶化或改善的研究。这份合同进行的研究和开发将提高现有四聚体试剂的质量、功能(例如灵敏度)和广度，并缩短生产时间。